Product Images Spironolactone

NDC number 51655-636-26 refers to Spironolactone Tablets, USP, containing 25mg per tablet. This prescription medication is available in a bottle containing 90 tablets, and it is limited to prescription use only. It is recommended to follow the package insert for dosage. The tablets should be stored at controlled room temperature and protected from direct light, and must be kept out of the reach of children. The repackager of the product is Northwind Pharmaceuticals, and the original manufacturer is listed as Zydus Pharmaceuticals (USA) Inc. The label includes the lot number and expiration date.*

This text appears to be a summary of a clinical trial investigating the efficacy of spironolactone versus a placebo. The trial included 822 individuals receiving the drug and 841 individuals receiving a placebo. A log-rank test was performed, and it resulted in a p-value of less than 0.001. It is not clear what the trial was investigating or what the time period (measured in months) on the x-axis represents.*

This is a tabulated dataset showing various characteristics of the subjects in a clinical trial evaluating the effectiveness of spironolactone compared to placebo. The table includes information on age, sex, race, ejection fraction (LVEF), heart failure, NYHA (New York Heart Association) classification, diabetes, serum creatinine levels, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, beta-blocker use, and the number of subjects in each subgroup. There is also a comparison of the efficacy of spironolactone versus placebo in improving the outcome.*